All In Biotech

Drug Trial Radar · NCT04695860

Anti-FGF23 (Burosumab) in Adult Patients With XLH

An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER

Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Jan 7, 2021

Primary completion

Mar 17, 2023

Study completion Mar 17, 2023

Sponsor

Lead sponsor
Wuerzburg University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kyowa Kirin, Inc.
First posted
Jan 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

X-linked hypophosphatemia (XLH) rare genetic disorder due by inactivating mutations in the PHEX gene leading to increased levels in FGF-23. Elevated FGF-23 reduces renal phosphate reabsorbtion and and limits 1-alpha hydroxylase driven Vitamin D activation, eventually leading to phosphate wasting, defective bone mineralization and additional health issues. Burosumab is a recombinant fully human IgG1 monoclonal antibody developed to treat XLH by binding FGF23, thereby restoring normal phosphate homeostasis. BUR03 is a Phase 3b open-label, single-arm, single-center study to confirm the efficacy and safety of Burosumab treatment in adult (age ≥18 years) XLH patients without upper age limit and irrespective of baseline pain level and to further evaluate the efficacy in this cohort and the assocaited effect of treatment on physical functioning, mobility and activity. The study aims at enrolling and treating 34 subjects with a confirmed diagnosis of XLH with q4w s.c. injection of Burosumab 1mg/kg body weight over 48 weeks. Primary objective is to attiain normal serum phosphorus levels, secondary objectives include key parameters of physical function and activity, mobility and mineral homeostasis.

Conditions

  • X-linked Hypophosphatemia

Interventions

  • BurosumabDrug

    Q4w, 1mg/kg Body weight, s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effect of Burosumab treatment on attaining serum phosphorus levels within the normal range in adults with XLHTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Unit, Orthopedic Department, Wuerzburg University

    Würzburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.